We determined that resistance to ciprofloxacin has emerged in enterococci over the last 5 years in our hospital, mainly in strains demonstrating the phenotype of high-level gentamicin resistance. All high-levelgentamicin-resistant isolates from 1985 and 1986 were susceptible, whereas 24% of isolates from 1989 and 1990 were resistant to ciprofloxacin. Plasmid and genomic DNA typing showed at least six unique strains exhibiting resistance, but one type accounted for 80%o of recent resistant isolates, suggesting a role for cross infection in the emergence of resistance.
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Enterococci are a common cause of nosocomial infection and are notable for their resistance to many antimicrobial agents (2, 9) . In recent years, increasing resistance to aminoglycosides (22) , penicillins (1) , and.vancomycin (18) has been noted. Ciprofloxacin has been shown to have activity in vitro against enterococci (6, 7, 15) and has been used in treating enterococcal infections (3, 5) . Although relatively high MICs and the existence of an inoculum effect have been noted, resistance to ciprofloxacin has been uncommon (6, 7, 11, 15, 21) .
In both the acute-care and long-term-care facilities of the Ann Arbor Veterans Affairs Medical Center, the majority of enterococci have high-level resistance to aminoglycosides (22, 23) . We determined whether resistance to ciprofloxacin among enterococcal isolates had increased from 1985 and 1986 to 1989 and 1990. Additionally, we determined whether resistance was predominantly in high-level-aminoglycosideresistant strains and whether one strain or multiple strains of ciprofloxacin-resistant enterococci had emerged in our facility. Enterococci were screened for resistance to ciprofloxacin, as described previously (4), by dotting an inoculum of 104 CFU/ml of an overnight culture suspended in saline onto
Strains of
Mueller-Hinton agar containing 4 ,ug of ciprofloxacin per ml.
MICs for infecting isolates from 1989 and 1990 were determined in the Clinical Microbiology Laboratory by the API Uniscept microdilution broth method (Analytab); the MICs for susceptible isolates were < 1.0 ,ug/ml, while those for resistant strains were >4.0 ,ug/ml. Thirty randomly chosen high-level-gentamicin-resistant, ciprofloxacin-resistant isolates from 1989 and 1990 were selected for extended susceptibility testing by microtiter broth dilution and both plasmid DNA and genomic DNA analyses. Susceptibility testing showed all these isolates to require ciprofloxacin MICs of >25 p,g/ml and gentamicin MICs of >2,000 ,g/ml. For 16 aminoglycoside-resistant isolates from 1985 and 1986, gentamicin MICs were also found to be >2,000 ,ug/ml but ciprofloxacin MICs ranged from 0.4 to 1.2 ,ug/ml. For plasmid DNA analysis, isolates were lysed and plasmid DNA was isolated according to the method described by Zervos et al. (20) , with the added step that the plasmid DNA samples were incubated with 1 ,ul of 5-mg/ml RNase for 1 h at 37°C prior to electrophoresis on 0.7% agarose gels. Lambda DNA (GIBCO-BRL, Grand Island, N.Y.) digested with HindIII was used as a size standard. The gels were run for 3 to 4 h at 75 V. The gels were stained with 1-p,g/ml ethidium bromide for 10 min, destained with distilled H20 for 1 to 10 h, and photographed with UV illumination.
Genomic DNA from the enterococcal isolates was prepared according to the method described by Murray et al. (10) Among strains colonizing residents of the long-term-care facility, increasing ciprofloxacin resistance was noted when strains isolated in the first 8 months of the study (July 1989 to February 1990, 8% ciprofloxacin resistant) were compared with those isolated in the second 8 months of the study (March 1990 to October 1990, 17.8% ciprofloxacin resistant) (X2 = 6.6, P = 0.01).
Examination of 30 enterococcal isolates by plasmid profiles and contour-clamped homogeneous-electric-field electrophoresis of SmaI-digested DNA revealed 6 unique strains demonstrating resistance. However, one dominant pattern was seen in 24 (80%) of the isolates examined.
In the short time that ciprofloxacin has been commercially available, increasing resistance has been described for a variety of different microorganisms, including Pseudomonas aeruginosa (12) , other gram-negative aerobic bacilli (8) , and Staphylococcus aureus, especially methicillin-resistant strains (4, 17 (8) .
Most ciprofloxacin resistance was noted in enterococci showing high-level aminoglycoside resistance. On the basis of DNA patterns manifested by the strains tested, cross infection appeared to play a substantial role in the spread of ciprofloxacin resistance, an observation similar to that noted with high-level gentamicin resistance and beta-lactamase production in enterococci (13, 14, 19, 20) .
The role of long-term-care facilities in the spread of antibiotic-resistant bacteria, such as ciprofloxacin-resistant enterococci, remains to be determined. Previous studies have documented the emergence of gentamicin-resistant (23) and ampicillin-resistant (16) enterococci in the long-termcare setting. In some cases, introduction of antibiotic-resistant enterococci into the acute-care setting from a long-termcare facility has been documented (19) , but it also seems likely that patients may enter the long-term-care facility already colonized with antibiotic-resistant enterococci acquired in the hospital (13, 23) . Given the trend for increasing resistance to ciprofloxacin in S. aureus, enterococci, and gram-negative bacilli (4, 8) , it seems likely that ciprofloxacin will be of less use in the future in treatment of various infections in the long-term-care setting. 
